In addition to direct targeting of BMPR2 pathway, specific manipulation of some BMPR2 signaling-related RNAs, metabolites, chemokines and enzymes still holds great promise in treatment of PAH. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.